Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair thickening after using topical minoxidil and oral finasteride for about 5 months and is considering switching from finasteride to RU58841. Other users encourage the original poster to continue the current treatment due to the positive results.

Hair regrowth treatments for cis-males include Minoxidil, Finasteride, and RU58841. Estrogen and testosterone blockers can help restore hair loss but may not suit everyone.

Redensyl, which is a topical alternative to Minoxidil for hair loss. It may have advantages such as not making the hair greasy and lasting longer after discontinuing use than minoxidil. There are some positive reports from users, but also some negative ones, so it's unclear how effective this treatment will be in comparison to Minoxidil and other treatments like Finasteride or RU58841.

A user sharing their positive experience with taking finasteride as part of their hair loss treatment regimen, which also included biotin, Nizoral Shampoo, OGX Biotin & Collagen Shampoo, and iRestore Laser Cap. Others shared their own experiences and advice on treating hair loss.

A user claims to see new baby hairs after using peppermint and castor oil for nearly two weeks, but others are skeptical, attributing the appearance of new hair to the way the hair is styled or pulled back.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

The conversation discusses a user's positive experience with a hair loss treatment routine involving dutasteride, oral minoxidil, and Nourkrin Man, with no side effects reported. Other users share their experiences with similar treatments, discussing side effects like heart palpitations and depression, and offer advice on obtaining prescriptions affordably.

1 mg dutasteride may be sufficient for most people, with higher doses showing diminishing returns. Combining dutasteride with minoxidil and ketoconazole can enhance results, but oral minoxidil may cause side effects.

Finasteride is preferred over dutasteride due to its longer history, more research, and FDA approval, despite dutasteride being more potent. Users report varied side effects, influencing personal treatment choices.

The user experienced significant hair regrowth using finasteride and minoxidil, leading to doubts about proceeding with a planned hair transplant. Many suggest postponing the transplant to save grafts for future needs, as the current results are impressive.

Stopping minoxidil causes significant hair loss, as continued use is necessary for maintaining gains. Combining minoxidil with finasteride may help maintain hair, but both treatments are typically lifelong commitments.

BackToTheFutehair's 3.5 month progress update on their hair loss treatment regimen of finasteride, minoxidil, and microneedling which has led to a significant improvement in thickness and life to the hair. Others have provided encouragement and advice for future treatments.

The user's experience and success with taking finasteride to treat hair loss, which is confirmed by other users who have taken it without side effects. The user also advises that consulting a doctor before starting any kind of treatment for hair loss is important, as opposed to relying on self-made remedies available online.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation discusses the potential benefits and risks of using Methionine and Glycine for hair loss, with concerns about cancer risk if not balanced properly. The user seeks opinions on these amino acids for hair health and overall benefits.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

The user experienced reduced hair loss using an online serum but found it too expensive and is seeking a vendor for ptd-dbm. They are also interested in KY19382 but are unable to find it.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Male pattern baldness (MPB) may be an early warning sign for type 2 diabetes due to its association with insulin resistance. Treatments discussed include testosterone therapy and finasteride, which affects hormone levels related to hair loss and insulin sensitivity.

The user is experiencing hair loss and has tried various treatments including topical and oral finasteride, minoxidil, dutasteride, and ketoconazole, but continues to lose hair. They are considering alternative solutions like hair systems due to the lack of improvement and a scalp condition called CVG.

Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stem cells and shows promise in treating hair loss, unlike Pelage's PP405.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.